Background
==========

Over the past few years, genome-wide association studies (GWAS) have successfully identified thousands of genetic loci associated with a variety of diseases and phenotype traits \[[@B1]\]. However, because of the limited resolution of microarray-based genotyping platforms, a vast majority of the human genome is not yet genotyped directly in GWAS. Since 2004, the advance of next-generation sequencing technologies has substantially lowered the cost of DNA sequencing. Nevertheless, it is still expensive to perform whole genome sequencing on a large cohort of samples, so reducing the cost by sequencing the most informative regions is a desirable approach. The human exome consists of 1% of the human genome but harbors 85% of disease-related variants \[[@B2]\]. Therefore, the cost of exome sequencing is typically only one-sixth that of whole genome sequencing \[[@B3]\]. Several commercial exome-capture platforms are currently available, each with a different design focus \[[@B4]-[@B6]\].

It is, however, still unclear whether exome sequencing is able to capture genetic variants associated with complex diseases. The objective of this project is to examine how much we could gain from exome sequencing compared with whole genome sequencing.

Methods
=======

For this study, we used a pedigree-based sample from the Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Ethnic Samples (T2D-GENES) Consortium provided by the Genetics Analysis Workshop 18 (GAW18). Whole genome sequence data was available for 959 participants from 20 families; 464 participants were directly sequenced and 495 were imputed from GWAS data. This data was cleaned of Mendelian errors prior to distribution. A total of 8,348,674 single-nucleotide polymorphisms (SNPs) were identified across all the odd-numbered chromosomes. Among them, 4,152,114 were common variants with a minor allele frequency (MAF) ≥1%. In addition, 425,734 common variants were identified by GWAS.

The data set contains phenotypes measured at 4 exams. At each exam, the following characteristics were recorded: age, hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of blood pressure medications, and smoking status. Hypertension is associated with a variety of diseases, such as stroke \[[@B7]\], diabetes \[[@B8]\], and heart failure \[[@B9]\]. The use of blood pressure medications would counteract the effect of genetic variations and introduce bias to the association analysis, so we excluded subjects using blood pressure medications or without covariate information.

This project used SBP at the baseline exam as the primary outcome, both for real and simulated phenotypes. The data was preprocessed using the PLINK software package \[[@B10]\]. Our model included SBP as the response variable and genotype data as the independent variable adjusting for age, gender, and smoking status. To account for family structure, we used a linear mixed-effects model as implemented in the \"kinship\" R package. The functional implication of genetic variations was predicted by ANNOVAR \[[@B11]\].

Because only the whole genome sequence was available, we mimicked the exome sequence by restricting the analysis to targeted regions designed by the 3 most common commercial exome capture platforms, Agilent SureSelect Human All Exon 50Mb, NimbleGen SeqCap EZ Exome Library v2.0, and Illumina TrueSeq Exome Enrichment. We assumed all the SNPs within the targeted regions were successfully captured. (Table [1](#T1){ref-type="table"} lists the number of SNPs captured by each exome platform.) On average, each platform captured approximately 133,000 SNPs, or approximately 1.6% of whole genome sequencing.

###### 

Number of variants captured by each platform

  Platform                       Number of variants   Number of common variants
  ------------------------------ -------------------- ---------------------------
  Whole genome sequencing        8,348,674            4,152,114
  Exome sequencing (Agilent)     129,204              58,091
  Exome sequencing (Illumina)    156,910              70,347
  Exome sequencing (NimbleGen)   113,150              50,000
  GWAS SNPs                      453,285              425,734

Results
=======

Figure [1](#F1){ref-type="fig"} shows the Manhattan plot of common variants across all odd-numbered chromosomes. A few peaks could be observed in chromosomes 3 and 9, indicating that the variants at these loci might be associated with SBP. Table [2](#T2){ref-type="table"} lists the top 30 SNPs from whole genome sequencing, and Table [3](#T3){ref-type="table"} lists the top 10 SNPs from GWAS together with 3 exome-sequencing platforms. The most significant SNP for the whole genome sequencing is chr3:106206487 (rs2590204, *p*= 1.1 × 10^−7^). The SNP is located within a gene desert, and the closest gene is *CBLB*, which encodes the E3 ubiquitin-protein ligase. The remaining top SNPs are all located within the introns or upstream of *PSIP1*, which is why they were not captured by the 3 exome platforms. The most significant SNP identified by all 3 exome platforms was chr7:11022564 (rs218965, *p*= 8.8 × 10^−7^), which is a synonymous mutation in *PHF14*. GWAS was able to pick up another SNP, chr9:15472139 (rs2777950, *p*= 7.5 × 10^−7^), which is located within the introns of *PSIP1*.

![**Manhattan plot of common variants associated with SBP**. Red line is the Bonferroni *p*value cutoff.](1753-6561-8-S1-S38-1){#F1}

###### 

Most significant variants in whole genome sequencing

  Rank   SNP           *p*Value   Function     Rank   SNP           *p*Value   Function     Rank   SNP          *p*Value   Function
  ------ ------------- ---------- ------------ ------ ------------- ---------- ------------ ------ ------------ ---------- ------------
  1      3:106206487   1          Intergenic   11     5:144654771   5.3E-07    Intergenic   21     7:11022564   8.8E-07    Exonic
  2      9:15503905    1.3E-07    Intronic     12     17:63733954   5.3E-07    Intronic     22     7:11025635   8.8E-07    Intronic
  3      9:15500315    1.9E-07    Intronic     13     9:15396745    5.5E-07    Intergenic   23     7:11027754   8.8E-07    Intronic
  4      9:15501713    1.9E-07    Intronic     14     9:15527348    6.7E-07    Intergenic   24     7:11016614   9.4E-07    Intronic
  5      9:15501753    1.9E-07    Intronic     15     9:15501422    7.1E-07    Intronic     25     7:11008221   1.0E-06    Intergenic
  6      9:15500150    2.8E-07    Intronic     16     9:15472139    7.5E-07    Intronic     26     9:15459251   1.0E-06    Intronic
  7      9:15528010    3.1E-07    Intergenic   17     15:92024157   7.5E-07    Intergenic   27     7:11022230   1.0E-06    Exonic
  8      9:15482976    3.3E-07    Intronic     18     9:15396695    8.4E-07    Intergenic   28     7:11025638   1.1E-06    Intronic
  9      9:15498495    3.7E-07    Intronic     19     7:11016690    8.8E-07    Intronic     29     7:11015444   1.1E-06    Intronic
  10     9:15466033    4.0E-07    Intronic     20     7:11018224    8.8E-07    Intronic     30     9:15397233   1.1E-06    Intergenic

###### 

Most significant variants in exome sequencing and GWAS

  ------ ------------- ---------- ------------ ------------- ---------- ------------ ------------- ---------- ---------- ------------- ---------- ----------
  Rank   GWAS SNPs     Agilent    Illumina     NimbleGen                                                                                          
         SNP           *p*Value   Function     SNP           *p*Value   Function     SNP           *p*Value   Function   SNP           *p*Value   Function
  1      9:15472139    7.5E-07    Intronic     7:11022564    8.8E-07    Exonic       7:11022564    8.8E-07    Exonic     7:11022564    8.8E-07    Exonic
  2      7:11022564    8.8E-07    Exonic       7:11022230    1.0E-06    Exonic       7:11022230    1.0E-06    Exonic     7:11022230    1.0E-06    Exonic
  3      7:11008221    1.0E-06    Intergenic   9:15468480    4.4E-06    Intronic     7:94927677    2.9E-06    UTR3       9:15571630    3.2E-05    Exonic
  4      7:11022230    1.0E-06    Exonic       7:41661724    2.9E-05    Intergenic   7:94921491    8.3E-06    UTR3       9:14863863    7.2E-05    Exonic
  5      7:11015444    1.1E-06    Intronic     9:15571630    3.2E-05    Exonic       9:15571630    3.2E-05    Exonic     3:125859012   7.4E-05    Intronic
  6      9:15528290    1.1E-06    Intergenic   3:184766392   3.9E-05    Intronic     3:184770380   3.9E-05    UTR3       17:64210580   7.5E-05    Exonic
  7      9:15443430    1.4E-06    Intronic     3:184769911   4.5E-05    UTR3         3:184769911   4.5E-05    UTR3       7:44608718    7.9E-05    Intronic
  8      9:15469733    1.7E-06    Intronic     3:184769941   4.5E-05    UTR3         3:184769941   4.5E-05    UTR3       1:212798260   1.0E-04    Exonic
  9      3:106199956   2.2E-06    Intergenic   9:14863863    7.2E-05    Exonic       7:94921543    6.8E-05    UTR3       1:210761365   1.2E-04    Exonic
  10     9:15446868    2.3E-06    Intronic     17:64210580   7.5E-05    Exonic       9:14863863    7.2E-05    Exonic     7:2414142     1.2E-04    Intronic
  ------ ------------- ---------- ------------ ------------- ---------- ------------ ------------- ---------- ---------- ------------- ---------- ----------

Because we performed thousands of tests, it is likely that many SNPs were false positives even if they reached the nominal significance cutoff. The simplest way to adjust for multiple testing is by Bonferroni correction \[[@B12]\], which uses a cutoff equivalent to 0.05 divided by the number of tests. So a SNP is claimed significant only if its *p*value is less than 1.2 × 10^−8^for the whole genome sequencing. Given that less than 2% of SNPs were tested in exome sequencing, the *p*value cutoffs would be 8.6 × 10^−7^, 7.1 × 10^−7^, and 6.1 × 10^−7^for Agilent, Illumina, and NimbleGen, respectively. For GWAS, the *p*value cutoff would be 1.2 × 10^−7^. Given these cutoffs, none of our top SNPs were significant.

However, Bonferroni correction is usually too conservative because of the linkage disequilibrium between SNPs. Several studies have been conducted to estimate the appropriate significance cutoffs for genetic tests \[[@B13]-[@B15]\]. Here we chose the false discovery rate (FDR) \[[@B16]\] to control type I error. Table [4](#T4){ref-type="table"} shows the number of significant SNPs that met different FDR thresholds in each platform. With FDR \<5%, all 3 exome platforms had 2 significant SNPs, whereas none of GWAS SNPs or whole genome SNPs were significant. With the increasing FDR, we observed that more SNPs became significant. The most significant SNP for whole genome sequencing reached 13% of FDR. The results can be visualized in the Q-Q plots in Figure [2](#F2){ref-type="fig"}. Two SNPs in exome sequencing obviously deviated from the diagonal line, suggesting that they were significantly associated with SBP. Such deviation is absent from the whole genome sequencing. No inflated type I error was observed in all the platforms because the genomic control λ was close to 1.

###### 

Number of SNPs passing FDR threshold in each platform

  ------------------- ------------- -------------- --------------- ---------- ------------------
  **FDR threshold**   **Agilent**   **Illumina**   **NimbleGen**   **GWAS**   **Whole genome**
  5%                  2             2              2               0          0
  10%                 3             3              2               10         0
  15%                 3             4              2               18         40
  ------------------- ------------- -------------- --------------- ---------- ------------------

![Q-Q plots of common variants associated with SBP for whole genome sequencing and exome sequencing](1753-6561-8-S1-S38-2){#F2}

We also performed association tests on the 200 simulated SBP phenotypes. The analysis was limited to SNPs at chromosome 3 because of the computational burden. On average, whole genome sequencing identified 163 significant hits per run, whereas exome sequencing identified 10, 7, and 7 for Agilent, Illumina, and NimbleGen, respectively. However, because over 50 times more SNPs were tested, whole genome sequencing did not show a significant advantage over exome sequencing in terms of identifying independent loci.

Discussion
==========

In this project, we compared the performance of whole genome sequencing with exome sequencing in a family-based association study. After correcting for multiple testing, we did not find great benefit from whole genome sequencing compared to exome sequencing. Our results suggest that exome sequencing is a cost-effective way to capture disease-related variants. Given the lower cost, exome sequencing allows a larger number of samples to be sequenced, which would significantly increase the statistical power for association studies.

One advantage of exome sequencing is that it focuses on the most informative proportion of the human genome. Therefore, the results are quite straightforward to interpret. It also lowers the requirement for computational resources and data storage. For example, the volume of exome sequence data is less than one-fifteenth that of whole genome sequence data. In addition, tools to efficiently analyze whole genome sequencing are still at an early stage.

Nevertheless, exome sequencing also has several intrinsic problems. Because of its heterogeneous capture capability, exome sequencing might introduce bias as a result of fragment size and GC content, which could result in ambiguous mapping and reduce the depth of coverage in the targeted regions. Exome sequencing also has very limited power to detect structural variations that are important to many diseases \[[@B17]\]. It is also worth noting that most of high penetrance variants that cause Mendelian diseases are very rare, thus association analysis is usually not the best way to study these diseases. Linkage analysis traditionally has been used for the purpose. Given that many common variations were located outside of the exome, whole genome sequencing would provide a better resolution for linkage analysis. We anticipate that the decreasing cost of sequencing and recent efforts to annotate the functional genome (eg, the ENCODE project \[[@B18]\]) will make whole genome sequencing more attractive and eventually lead to the retirement of exome sequencing.

Conclusions
===========

Exome sequencing is an effective method to identify disease-related variants in family-based association studies. As the cost of sequencing drops and our knowledge of the functional genome improves, we anticipate that whole genome sequencing will prove to be a better solution for future genetics research.
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